The Norwegian Immunotherapy in Multiple Myeloma Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSt. Olavs Hospital
About this trial
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
Eligibility criteria
Qualifiers
Participants age ≥ 18 years
Prior diagnosis of one of the following
Multiple myeloma as defined according to IMWG criteria
Primary plasma cell leukemia as defined according to IMWG consensus definition
Disqualifiers
None
Trial design
Treatments tested in this trial
- Teclistamab
- Elranatamab
- Ciltacabtagene Autoleucel
- Talquetamab
- Idecabtagene vicleucel
Treatment groups
No treatment groups listed
Sponsors and collaborators
St. Olavs Hospital
Lead sponsor
Norwegian University of Science and Technology
Collaborator
Haukeland University Hospital
Collaborator
Helse Stavanger HF
Collaborator
Oslo University Hospital
Collaborator
University Hospital, Akershus
Collaborator
Sykehuset i Vestfold Hospital Trust
Collaborator
University Hospital of North Norway
Collaborator
Ålesund Hospital, Norway
Collaborator
Helse Nord-Trøndelag HF
Collaborator
Sorlandet Hospital HF
Collaborator
Førde Hospital Trust
Collaborator
Molde Hospital
Collaborator
Bodø Hospital, Norway
Collaborator
Helse Fonna
Collaborator
Volda Hospital
Collaborator
Diakonhjemmet Hospital
Collaborator
Telemark Hospital Trust
Collaborator
Kristiansund Hospital
Collaborator
Vestre Viken Hospital Trust
Collaborator
Lovisenberg Diakonale Hospital
Collaborator
Sykehuset Innlandet HF
Collaborator
Source ClinicalTrials.gov